Arkolith/Insider Trading/EBS/Form 4

Dayal Sujata Tyagi

DirectorEmergent BioSolutions Inc. (EBS) · full profile →Form 4 · filed May 4, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$116K
Net Open-Market Flow
-$116K
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 1, 2026Sell(S)13K$8.36$107K102K
May 1, 2026Sell(S)980$8.94$9K101K
Apr 30, 2026Grant(A)25K—$0114K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 30, 2026Grant(A)11K—$011K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001536908-26-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML